Biolegend, 423304, Cell Activation Cocktail (with Brefeldin A)
400microl
Catalog Number: 423304
Send an RFQ.
Category
Pack Size4 vials
Loading…
| Formulation | Cell Activation Cocktail (with Brefeldin A) is composed of PMA, ionomycin, and Brefeldin A in DMSO (500X). |
|---|---|
| Concentration | Each vial of this cocktail contains phorbol-12-myristate 13-acetate (40.5 µM), ionomycin (669.3 µM), and Brefeldin A (2.5 mg/ml) in DMSO (500X). |
| Storage & Handling | Store cocktail at -70°C upon receipt. Protect from light. Avoid repeat freeze/thaw cycles. |
| Application | Activ, FC, ICFC - Quality tested |
| Recommended Usage | Cat. No. 423303 contains 100 µL of cocktail, formulated at 500X, that can be used for activating 50 mL of cells of various types. Cat. No. 423304 contains 400 µL (4 vials x 100 µL per vial) of cocktail, formulated at 500X, that can be used for activating 200 mL of cells of various types. |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| Cell Activation Protocol: 1. Resuspend cells of interest in desired cell culture medium. Recommended cell suspension is between 1-2 x 106 cells/mL, although effective activation can be obtained with higher or lower concentration. 2. Completely thaw vials in 37°C water bath. 3. Add 2 µL of the cocktail to each mL of cell suspension. 4. Incubate cells at 37°C in a CO2 incubator for 6 hours or the time period of interest. 5. Harvest activated cells and centrifuge at 350g for 5 minutes. Discard supernatant. 6. Add 2.5 mL of Cell Staining Buffer (Cat. No. 420201) to the cell pellet, mix by vortex or pipetting, then centrifuge at 350g for 5 minutes. Discard supernatant. 7. Repeat step 6. 8. Cells are now ready to be tested for surface markers or proteins of interest. Note: Activation of cells overnight (>12 hours) with Brefeldin A is generally not recommended due to some level of toxicity. Under these conditions, it is recommended to use Cell Activation Cocktail without Brefeldin A (Cat. No. 423301), and then add monensin (Cat. No. 420701) at appropriate concentrations. This product is temperature sensitive; repeated freeze/thaw is not recommended. Intracellular and surface flow staining, as well as ELISA, can be performed following activation of cells with this cocktail. |
| Product Citations | Makker P, et al. 2017. PLoS One. 10.1371/journal.pone.0170814. PubMed Freimer JW, et al. 2022. Nat Genet. 54:1133. PubMed Li L, et al. 2022. Cancer Immunol Res. 10:1475. PubMed Jia DJ, et al. 2022. Gut Microbes. 14:2145843. PubMed Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed Nguyen HM, et al. 2023. Cancers (Basel). 15:. PubMed Yang Y, et al. 2023. Front Immunol. 14:1033497. PubMed Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed Yi X, et al. 2023. Signal Transduct Target Ther. 8:107. PubMed Wu Q, et al. 2023. Theranostics. 13:1381. PubMed Mohammadpour H, et al. 2023. Cell Rep. 42:112250. PubMed Zhou C, et al. 2023. Int J Biol Sci. 19:1471. PubMed Imai H, et al. 2023. iScience. 26:106822. PubMed Benson LN, et al. 2022. Circ Res. 130:1550. PubMed Chae CS, et al. 2022. Cancer Discov. 12:1904. PubMed Luo Z, et al. 2022. Int J Mol Sci. 23: . PubMed Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed Hao J, et al. 2022. Cell Rep. 41:111804. PubMed Mulholland M, et al. 2022. JACC CardioOncol. 4:635. PubMed Zhao Q, et al. 2023. Nutrients. 15: . PubMed Wang R, et al. 2023. iScience. 26:105954. PubMed Sun L, et al. 2023. Mol Med Rep. 27: . PubMed Sohn J, et al. 2022. Mol Oral Microbiol. 37:42. PubMed Asrir A, et al. 2022. Cancer Cell. 40:318. PubMed Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed Zhang H, et al. 2022. J Exp Med. 219:. PubMed Zhou T, et al. 2020. Nature. 583:609. PubMed Li Q, et al. 2022. Cell Rep. 40:111308. PubMed Li X, et al. 2022. Nat Commun. 13:2794. PubMed Volta V, et al. 2021. Nat Commun. 12:6979. PubMed Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed Jiang Q, et al. 2019. Front Oncol. 1.205555556. PubMed Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed Liu F, et al. 2020. Oncoimmunology. 9:1746573. PubMed Rao E, et al. 2021. Sci Immunol. 6:. PubMed Zhou H, et al. 2022. J Clin Invest. 132:. PubMed Papadas A, et al. 2022. Cell Rep. 40:111201. PubMed Dai B, et al. 2022. Theranostics. 12:7603. PubMed Liu S, et al. 2017. J Pharmacol Sci. 10.1016/j.jphs.2017.02.001. PubMed Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed Xu J, et al. 2020. Cell Death Dis. 1.106944444. PubMed Watkins–Schulz R, et al. 2019. Biomaterials. 205:94. PubMed Jones KI, et al. 2018. EMBO Mol Med. 10:e9342. PubMed Cho S, et al. 2017. Sci Rep. 7:35. PubMed Du Y, et al. 2022. Nat Commun. 13:231. PubMed Gudgeon N, et al. 2022. Cell Rep. 40:111193. PubMed Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed Wei W, et al. 2022. mSystems. 7:e0046922. PubMed Yang J, et al. 2022. Microbiome. 10:149. PubMed Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed Jain RW, et al. 2018. Cell Rep. 25:3342. PubMed Wang J, et al. 2022. J Clin Invest. :. PubMed Hao C, et al. 2021. Frontiers in Cell and Developmental Biology. 9:695015. PubMed Creyns B, et al. 2020. Front Immunol. 1.740972222. PubMed Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed Lin J, et al. 2021. Nat Commun. 12:5321. PubMed Weiner, et al. 2021. Nature. 592:450. PubMed Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed Saito E, et al. 2019. Biomaterials. 222:119432. PubMed Guo Q, et al. 2021. Drug Des Devel Ther. 15:4559. PubMed Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed Pöysti S, et al. 2021. Eur J Immunol. 51:620. PubMed Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed Strobl J, et al. 2021. J Exp Med. 218:. PubMed Pan S, et al. 2021. Front Cell Dev Biol. 9:629306. PubMed Webb J, et al. 2015. Cancer Immunol Res. 3: 926-935. PubMed Yin S, et al. 2015. Sci Rep. 5: 14432. PubMed Wu H, et al. 2020. Br J Pharmacol. 177:402. PubMed Wang X, et al. 2020. Exp Ther Med. 19:3698. PubMed Gao J, et al. 2022. Front Immunol. 13:955812. PubMed Deng Z, et al. 2022. Front Oncol. 12:975408. PubMed Peng X, et al. 2021. Stem Cell Res Ther. 198:12. PubMed Chang T, et al. 2020. Aging (Albany NY). 12:21147. PubMed Li D, et al. 2020. Immunohorizons. 0.661805556. PubMed Kim ST, et al. 2019. J Immunother Cancer. 0.379166667. PubMed Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed Li N, et al. 2022. Nat Commun. 13:7281. PubMed Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed Kim ST, et al. 2021. J Immunother Cancer. 9:. PubMed Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed Prosser A, et al. 2021. STAR Protoc. 2:100810. PubMed Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed Zhang QW, et al. 2021. Am J Cancer Res. 11:2782. PubMed Xu L, et al. 2022. Front Immunol. 13:841141. PubMed |
|---|
| Gene ID | NA |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Cell Stimulation Cocktail, PMA/Ionomycin |
|---|
